Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

NCT03279614 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
45
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking University